Alembic Ltd, the maker of the cough preparation Glycodin which acquired part of Dabur’s pharmaceuticals business earlier this year is now eyeing a domestic maker of ophthalmic products as part of its inorganic growth strategy. “We plan to enter the ophthalmic segment through an acquisition in this space and we are in discussions to buy a company. The size of the deal could be about Rs100 crore,” said Chirayu R. Amin, chairman and managing director of Alembic. He declined to divulge further details.
Alembic ended 2006-07 with Rs700 crore in net sales.The company said its target would have expertise in manufacturing ophthalmic products. “We can build on these technologies to grow our presence in the ophthalmic segment, both in the domestic market as well as in the international markets,” said Pradeep Rane, president-formulations business, Alembic.
Ophthalmics is a niche segment and unlike other categories in the domestic pharmaceutical market which are crowded, few companies such as Allergan India Pvt. Ltd and Cipla Ltd have a significant presence in it.The domestic ophthalmology market is currently valued at around Rs400 crore and is growing at over 15%.
Read more in The Live Mint article.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment